I. Introduction
Angiogenesis is the process of formation of new blood vessels. It begins in utero and occurs throughout life. All metabolically active tissue in mammals and others require continuous supply of oxygen and nutrients for their survival. For this purpose new blood vessels are required in newly formed tissues and angiogenesis is the process that recruit new blood vessels signaled by pro-angiogenic molecules. Without blood vessels tumors can neither grow beyond a critical size nor metastasize to another organ 1 . On the other hand, without an efficient blood supply it is impossible to deliver anti-cancer drugs to all regions of a tumour.
Types
The Scotishanatomist John Hunter (1794) provided the first recorded scientific insights about angiogenesis. It is of two types.  Sprouting angiogenesis : it is characterized by sprouts composed of endothelial cells, which usually grow towards an angiogenic stimulus such as VEGF-A. It adds blood vessels to the portions of tissues that previously devoid of blood vessels.  Intussusceptiveangiogenesis : it forms blood vessels by a splitting process in which elements of interstitial tissues invade existing blood vessels.
A brief history of Angiogenesis  The term "Angiogenesis" was introduced by Dr. John Hunter to describe the formation of blood vessels in the reindeer antler in 1787.  In the year 1935, Dr. Arthur TremainHertig reported angiogenesis in the placenta of pregnant monkey  In 1971, Judah Folkman first described that tumour growth is dependent upon angiogenesis.  Adenosine is a metabolic regulator of angiogenesis. It is thought to serve as a negative feedback signal to maintain tissue oxygenation within a normal range. Granulocyte colony stimulating factor 7.
Angiogenic growth factors :
Hepatocyte Growth factor 8.
Interlenkin -8 9.
Leptin 10. Midkine 11.
Placental Growth factor 12.
Platelet-derived endothelical Growth Factor 13.
Platelet derived growth factor-BB 14. Imatinib is such an agent that targets bcr-abl proteins (it is a tyrosine kinase fusion protein that causes chronic myelogenous leukemia or CML) 5 . It was introduced in 1990 and approved in 2001 for the treatment of CML. .
Use of natural health products as anti-AngiogenicAgent :
Most anti-angiogenic drugs have cytotoxic affects that may lead to the destruction of functionally important cells along with the tumour cells. To overcome these problems, there is an restless search for a way that can ensure minimum harm with maximum benefit. It seems to be true the search for the weapon against cancer. Several outstanding discoveries have revealed that the weapon may be hidden in the world of herbs and phytochemicals.
In 1990, Ingber&et al isolated fumagillin from the fungus Aspergillusfumigatus and suggested that fumagillin have anti-angiogenic properties 10 . It was apioneering discovery that opened a new window in cancer research.
In the following paragraph, few interesting informations about natural products having anti angiogenic properties are discussed.
Curcumin :It was isolated from turmeric (Curcuma longa). It is reported from several studies that curcumin inhibits the transcription of two most critical angiogenesis factors -VEGF and b-FGF 11 . CD-13 is a membrane bound enzyme found on actively growing blood vessels. Curcumininhibits CD-13 activity 12 .
Resveratrol :It is a phytolexin found in grapes and wine. It inhibits VEGF-induced angiogenesis by disruption of reactive oxygen species -dependent src kinase activation and VE-cadherin tyrosine phosphorylation 13 . Epigallocatechin-3 gallate :It is extracted from green tea (Camellia sinensis). From rodent studies, it is reported that the compound have inhibitory effect on the transcription of VEGF 14 Quercetin :It is found in apples, onions, red grapes, citrus fruits, cherries, broccoli and leafy greens. It has antiangiogenic effects.
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II.
Conclusion :
Managing cancer is the biggest challenge for the biologists of this century. In every corner of the world thousands of scientists are engaged for searching a weapon to defeat this dangerous enemy. Though it is the fact that "We have miles to go" to get the ultimate success. The scenario of cancer research since last 25 years shows that biologists have already discovered various target points to attack by chemical or phytochemical products to destroy the cancer cells or to activate systems that inhibit their growth or regulate their death. But there are many difficulties to send the drug at the proper location to interact with the target component. Now, efforts are required to cross this barrier.
